Tirzepatide and Glucagon-like Peptide-1/Glucose-dependent Insulinotropic Polypeptide Therapy: Quality of Life, Filipino Diet Culture, and Safe Access
Aaron A. Funa, Renz Alvin E. Gabay · 2026
Read Tirzepatide and Glucagon-like Peptide-1/Glucose-dependent Insulinotropic Polypeptide Therapy: Quality of Life, Filipino Diet Culture, and Safe Access by Aaron A. Funa, Renz Alvin E. Gabay (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13639644.txt.
Description
Funa and Gabay wrote a letter in 2026 extending a study of switching diabetes patients from oral semaglutide to weekly tirzepatide. The original study found quality of life improved after the switch, even though blood sugar and weight barely changed at three months. The letter argues that GLP-1/GIP therapy, which mimics two gut hormones, should be judged by burden, expectations, and daily routine as well as by metabolism.
They suggest smaller rice portions, healthier main dishes, fewer sugary drinks, and planning for celebration meals without stigma. They warn that patients priced out of supervised care may buy unverified products online, with quality and dosing risks. Future studies, they argue, should track quality of life, motives, affordability, sourcing, and side effects together.
Catalog record
| CREATOR | Aaron A. Funa, Renz Alvin E. Gabay |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |